Perspective Therapeutics
CATX
43 hedge funds and large institutions have $4.12M invested in Perspective Therapeutics in 2020 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 11 increasing their positions, 3 reducing their positions, and 5 closing their positions.
267% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 3
100% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 5
13% more funds holding
Funds holding: 38 → 43 (+5)
5% more capital invested
Capital invested by funds: $3.93M → $4.12M (+$191K)
0.01% more ownership
Funds ownership: 0.98% → 0.99% (+0.01%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$370K |
| 2 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
+$221K |
| 3 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$85.3K |
| 4 |
VF
Virtu Financial
New York
|
+$64.3K |
| 5 |
HPWM
Highland Private Wealth Management
Bellevue,
Washington
|
+$30K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$44.2K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$31K |
| 3 |
AAS
Avantax Advisory Services
Dallas,
Texas
|
-$29K |
| 4 |
OCPWS
One Charles Private Wealth Services
Hingham,
Massachusetts
|
-$12K |
| 5 |
HWM
HighMark Wealth Management
St. Paul,
Minnesota
|
-$6K |
CATX Hedge Fund Activity: Q4 2020 in Review
43 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Perspective Therapeutics (CATX) for Q4 2020, worth a combined $4.12M — up 4.9% from $3.93M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new CATX positions and 5 closed out — a net gain of 5 holders — while 11 added to existing stakes and 3 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $370K. The largest seller was Bridgeway Capital Management, cutting an estimated $44.2K.
- 43 institutional investors held Perspective Therapeutics (CATX) as of Q4 2020, up from 38 in Q3 2020.
- Funds reported $4.12M of Perspective Therapeutics stock for Q4 2020, up 4.9% quarter-over-quarter.
- 10 funds opened new Perspective Therapeutics positions in Q4 2020 and 5 closed out, a net change of +5 holders.
- The largest Perspective Therapeutics buyer in Q4 2020 was Renaissance Technologies, an estimated $370K added.
- The largest Perspective Therapeutics seller in Q4 2020 was Bridgeway Capital Management, an estimated $44.2K sold.
Based on aggregated 13F filings for Q4 2020.